Carla Walker, APRN
Family · Fort Smith, ARNPI 1740704774
Payments from drug & device makers
Across 397 payments — averaging $14.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$970
- GSK$634
- Pfizer$501
- Amgen$499
- AstraZeneca$481
- Novo Nordisk$399
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,877100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 74 | $970 |
| GSK | 44 | $634 |
| Pfizer | 40 | $501 |
| Amgen | 29 | $499 |
| AstraZeneca | 23 | $481 |
| Novo Nordisk | 23 | $399 |
| Bayer | 25 | $369 |
| Biohaven Pharmaceuticals, Inc. | 26 | $230 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $206 |
| Lilly USA, LLC | 12 | $176 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $149 |
| Johnson & Johnson | 8 | $147 |
| Abbott | 9 | $144 |
| Novartis | 8 | $120 |
| Boehringer Ingelheim | 7 | $112 |
| Exact Sciences | 6 | $97 |
| Astellas Pharma US Inc | 5 | $82 |
| Sumitomo Pharma America, Inc. | 4 | $66 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| Upsher-smith Laboratories LLC | 2 | $44 |
| Alfasigma USA, Inc. | 3 | $40 |
| Dexcom, Inc. | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Merck | 2 | $30 |
| Amarin Pharma, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Corium, LLC | 1 | $20 |
| Averitas Pharma Inc. | 1 | $19 |
| Inari Medical, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Shield Therapeutics Inc | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$5,877 in reported general payments places this provider in the 90th percentile of 2,103 family providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 110 | $90,604 |
| OzempicSemaglutide | 38 | $49,124 |
| MyrbetriqMirabegron | 70 | $45,343 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $40,807 |
| TrulicityDulaglutide | 37 | $39,395 |
| JardianceEmpagliflozin | 43 | $38,595 |
| MounjaroTirzepatide | 24 | $35,401 |
| Nurtec OdtRimegepant Sulfate | 29 | $29,515 |
| EliquisApixaban | 44 | $28,145 |
| Repatha SureclickEvolocumab | 47 | $26,740 |
| JanuviaSitagliptin Phosphate | 24 | $21,012 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $13,044 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $7,848 |
| KerendiaFinerenone | 11 | $6,935 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $6,463 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $481 | $90,604110 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $176 | $74,79661 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $634 | $68,163114 claims |
| PfizerNurtec Odt, Eliquis | $501 | $57,65973 claims |
| Novo NordiskOzempic | $399 | $49,12438 claims |
| Astellas Pharma US IncMyrbetriq | $82 | $45,34370 claims |
| Boehringer IngelheimJardiance | $112 | $38,59543 claims |
| MerckJanuvia | $30 | $21,01224 claims |
| BayerKerendia | $369 | $6,93511 claims |
| AbbVieLinzess | $970 | $5,96111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,103 family providers in Arkansas.
Other family in Fort Smith
- Nina CopelandFort Smith$207K
- Amanda DavisFort Smith$46K
- Scarlett BoneFort Smith$16K
- Nathan WilliamsonFort Smith$15K
- Yong OunpraseuthFort Smith$14K
- Karen WilliamsFort Smith$11K
- Nycole OliverFort Smith$10K
- Bentlee RundellFort Smith$10K
- Nata MatthewsFort Smith$10K
- Emily ChristensenFort Smith$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.